Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92006541 | 9200654 | 1 | I | 2011 | 20130318 | 20130331 | 20130331 | EXP | DE-UCBSA-081467 | UCB | 54.00 | YR | F | Y | 0.00000 | 20130331 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92006541 | 9200654 | 1 | PS | VIMPAT | 1 | D | 22253 | ||||||||||||
| 92006541 | 9200654 | 2 | SS | VIMPAT | 1 | 200 MG/DAY | D | 22253 | |||||||||||
| 92006541 | 9200654 | 3 | C | ESLICARBAZEPINE | 1 | D | 0 | 1600 | MG | QD | |||||||||
| 92006541 | 9200654 | 4 | C | TOPIRAMATE | 1 | 400 MG/DAY | D | 0 | |||||||||||
| 92006541 | 9200654 | 5 | C | TOPIRAMATE | 1 | 350 MG/DAY | D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 92006541 | 9200654 | 1 | Epilepsy |
| 92006541 | 9200654 | 2 | Epilepsy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 92006541 | 9200654 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 92006541 | 9200654 | Epilepsy | |
| 92006541 | 9200654 | Grand mal convulsion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 92006541 | 9200654 | 1 | 20110813 | 0 |